MedPath

Ianalumab

Generic Name
Ianalumab
Drug Type
Biotech
CAS Number
1929549-92-7
Unique Ingredient Identifier
ZN2GQ3II96

Overview

Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).

Background

Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/06/26
Phase 2
Not yet recruiting
2024/12/02
Phase 3
Recruiting
2024/06/24
Phase 2
Recruiting
2024/05/13
Phase 1
Withdrawn
2023/11/18
Phase 3
Recruiting
2023/08/14
Phase 3
Recruiting
2023/06/02
Phase 2
Active, not recruiting
2022/12/16
Phase 3
Active, not recruiting
2022/12/16
Phase 3
Recruiting
2022/12/13
Phase 3
Recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath